Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Zetasizer APS Analyzes Sticky Proteins with No Cross-Contamination

Published: Monday, October 14, 2013
Last Updated: Sunday, October 13, 2013
Bookmark and Share
New application note published on Malvern Instruments website.

A new application note published on the Malvern Instruments website demonstrates the absence of any cross contamination when using the company’s Zetasizer APS (Auto Plate Sampler) to analyze known ‘sticky’ proteins.

The Zetasizer APS dynamic light scattering (DLS) system enables the automated measurement of multiple samples and has wide application in the rapid screening of proteins.

The risk of cross-contamination is a concern to many people when considering automated analysis in a multiwell format and the experiment was designed to thoroughly test the instrument’s capabilities. The application note can be downloaded at www.malvern.com/dlsautomation.

Setup and operation of the Zetasizer APS is straightforward and its stringent cleaning protocols are designed to ensure that no cross contamination occurs.

The work described in the new application note used familiar protein samples to demonstrate the lack of detectable cross-contamination.

Samples included insulin, in both “monomeric” (the insulin hexamer) and “oligomeric” forms, and Abeta, the amyloid beta peptide known for its stickiness and tendency to adhere to plastic. The Abeta sample was present in two forms, fibrillar and oligomeric.

The order in which samples were loaded onto the system was chosen so as to maximize the risk of cross-contamination.

The oligomeric insulin was dispensed first using a standard pipette, followed by the small and pure insulin, and then the larger polydisperse Abeta samples.

Since large protein aggregates scatter much more light than small pure protein samples, if cross-contamination were to occur the polydisperse Abeta sample would be detected within the small homogenous protein sample. The results show that after running multiple tests, there was no detectable cross contamination.

The Zetasizer APS delivers the same high sensitivity, high specification DLS measurements as other systems in Malvern’s established Zetasizer family.

The automated processing of samples in multiwell plates enables the generation of high quality DLS data with no user intervention, a major benefit in maximizing productivity.

The system’s highly practical data display capability allows easy retrieval of results of interest, eliminating the need to manually scan through all measurements. In addition, the Zetasizer APS plate navigator feature acts as a data mapping tool, for rapid screening of results to retrieve the information of most interest and subsequent in-depth investigation of selected data sets.

The separate temperature controls of the plate holder and the measurement cell allow the Zetasizer APS to maintain the protein samples in optimal condition until measurement. In addition, thermal trend measurements between 2°C to 90°C with 0.1°C degree precision can be defined.

The plate scheduler allows the user to graphically set up size and thermal trend measurements of various samples from the same plate using a variety of different SOPs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Time at Pittcon for new Malvern Systems
Malvern is exhibiting its particle characterization and rheology ranges at Pittcon 2006.
Thursday, January 05, 2006
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!